Safety of naltrexone in patients with cirrhosis.  Thompson R, Taddei T, Kaplan D, Rabiee A.  JHEP Rep. 2024 Apr 10;6(7):101095. doi: 10.1016/j.jhepr.2024.101095. PMID: 38961852; PMCID: PMC11220533. https://www.jhep-reports.eu/article/...

Faster approach for starting extended-release naltrexone to treat opioid use disorder shown effective  NIH-supported clinical trial addresses important barrier to opioid use disorder treatment.  Starting people with opioid use disorder...

Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial.  Shulman M, Greiner MG, Tafessu HM, et al.  JAMA Netw Open. 2024;7(5):e249744. doi:10.1001/jamanet...

Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications.  Beauregard ER, Maguire EG.  Ment Health Clin. 2024 Apr 1;14(2):102–6. doi: 10.9740/mhc.2024.04.102. PMCID: PMC11058323. https://ww...

Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder.  Green M, Veltri CA, Grundmann O.  Subst Abuse Rehabil. 2024 Apr 3;15:43-57. doi: 10.2147/SAR.S431270. PMID: 38585160; PMCID: PMC10999209. h...

Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients.  Ross RK, Nunes EV, Olfson M, Shulman M, Krawczyk N, Stuart EA, Rudolph KE  medRxiv [Pr...